SAN DIEGO, Nov. 7, 2022 /PRNewswire/ — NovoMedix, LLC (“NovoMedix”), a biotechnology company developing novel, multi-pathway modulators for fibrosis and cancer, today announced the presentation of new preclinical data on NMX2 at the 2022 American Heart Association Scientific Session, being held November 5-7, 2022 in Chicago, Illinois. The presentation is titled, “Dual AMPK Activator/mTOR Inhibitor […]